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Articles
Cause-specific mortality of children younger than 5 years 
in communities receiving biannual mass azithromycin 
treatment in Niger: verbal autopsy results from a 
cluster-randomised controlled trial 
Jeremy D Keenan, Ahmed M Arzika, Ramatou Maliki, Sanoussi Elh Adamou, Fatima Ibrahim, Mariama Kiemago, Nana Fatima Galo, Elodie Lebas, 
Catherine Cook, Benjamin Vanderschelden, Robin L Bailey, Sheila K West, Travis C Porco, Thomas M Lietman, on behalf of the MORDOR-Niger 
Study Group*
Summary
Background The Macrolides Oraux pour Réduire les Décès avec un Oeil sur la Résistance (MORDOR) trial found that 
biannual mass distribution of azithromycin to children younger than 5 years in Niger reduced the primary outcome 
of all-cause mortality by 18%. We aimed to determine the causes of mortality among deceased children using verbal 
autopsy.
Methods In this 2-year cluster-randomised controlled trial, 594 community clusters in Niger were randomly allocated 
(1:1 ratio) to receive biannual mass distributions of either oral azithromycin (approximately 20 mg per kg of bodyweight) 
or placebo targeted to children aged 1–59 months. Participants, study investigators, and field workers were masked to 
treatment allocation. Between Nov 23, 2014, and July 31, 2017, 3615 child deaths were recorded by use of biannual 
house-to-house censuses, and verbal autopsies were done between May 26, 2015, and May 17, 2018, to identify cause of 
death. Cause-specific mortality, as assessed by verbal autopsy, was a prespecified secondary outcome. This trial is 
completed and is registered with ClinicalTrials.gov, NCT02047981.
Findings Between Nov 23, 2014, and July 31, 2017, 303 communities (n=40 375 children at baseline) in Niger received 
mass azithromycin and 291 communities (n=35 747 children at baseline) received placebo. Treatment coverage was 
90·3% (SD 10·6) in the azithromycin group and 90·4% (10·1) in the placebo group. No communities were lost to 
follow-up. In total, 1727 child deaths in the azithromycin group and 1888 child deaths in the placebo group were 
reported from the population censuses. Of these, the cause of death for 1566 (90·7%) children in the azithromycin 
group and 1735 (91·9%) children in the placebo group were ascertained by verbal autopsy interviews. In the 
azithromycin group, 437 (27·9%) deaths were due to malaria, 252 (16·1%) deaths were due to pneumonia, and 
234 (14·9%) deaths were due to diarrhoea. In the placebo group, 493 (28·4%) deaths were due to malaria, 275 (15·9%) 
deaths were due to pneumonia, and 251 (14·5%) deaths were due to diarrhoea. Relative to communities that received 
placebo, child mortality in communities that received azithromycin was lower for malaria (incidence rate ratio 0·78, 
95% CI 0·66–0·92; p=0·0029), dysentery (0·65, 0·44–0·94; p=0·025), meningitis (0·67, 0·46–0·97; p=0·036), and 
pneumonia (0·83, 0·68–1·00; p=0·051). The distribution of causes of death did not differ significantly between the 
two study groups (p=0·98).
Interpretation Mass azithromycin distribution resulted in approximately a third fewer deaths in children aged 
1–59 months due to meningitis and dysentery, and a fifth fewer deaths due to malaria and pneumonia. The lack of 
difference in the distribution of causes of death between the azithromycin and placebo groups could be attributable to the 
broad spectrum of azithromycin activity and the study setting, in which most childhood deaths were due to infections.
Funding Bill & Melinda Gates Foundation.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Despite considerable improvements over the past few 
decades, childhood mortality remains far above the 
Sustainable Development Goals for many regions in 
sub-Saharan Africa.1,2 Most childhood deaths in Africa are 
due to infectious diseases.2 The increasing availability of 
vaccines, coupled with improvements in primary health-
care systems, promises to further increase childhood 
survival.3,4 Nevertheless, additional interventions to 
further reduce childhood mortality would be welcome.
The Macrolides Oraux pour Réduire les Décès avec 
un Oeil sur la Résistance (MORDOR) cluster-randomised 
trial was done in three study sites located in sub-Saharan 
Africa: Malawi, Niger, and Tanzania. Children aged 
1–59 months in communities in these three countries 
were randomly assigned to receive biannual mass 
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treatment of either azithromycin or placebo to determine 
the efficacy of mass antibiotic distributions for reducing 
childhood mortality. Cluster randomisation was chosen 
because antibiotic consump tion could have direct effects 
on treated individuals and also indirect spillover effects 
on untreated children (ie, herd protection).5 All-cause 
mortality among children younger than 5 years was 
approximately 14% lower in communities that received 
azithromycin than in those that received placebo across 
all sites.6 The largest effect was observed in Niger, 
where all-cause mortality was 18% lower in communities 
that received azithromycin than in those that received 
placebo. However, cause-specific mortality was not 
explored in depth.6 In this study, we aimed to compare 
cause-specific mortality in children younger than 5 years 
in Niger between the two study groups using verbal 
autopsy results. Cause-specific mortality was a 
prespecified secondary outcome of the MORDOR trial. 
We hypothesised that child deaths due to infectious 
diseases would be less common in communities that 
received azithromycin than in communities that received 
placebo.
Methods
Study design and participants
The MORDOR trial was a parallel-group, cluster-
randomised trial in which communities in Malawi, Niger, 
and Tanzania were randomly assigned to receive biannual 
mass distributions of either oral azithromycin or placebo 
between Nov 23, 2014, and July 31, 2017, with study drugs 
distributed to all children aged 1–59 months in the 
community. Children were monitored approximately 
every 6 months by use of a population census. A shortened 
verbal autopsy was done at each country’s study site for 
child deaths reported in the census by use of a 
standardised questionnaire, the results for which have 
been reported separately.6 Although the shortened verbal 
autopsy was the only cause of death assessment required 
across the study sites of all three countries, individual 
study sites were allowed to do more intensive assessments 
if desired. Thus, in addition to the shortened verbal 
autopsy questionnaire, the full 2007 WHO verbal autopsy 
questionnaire was also done in Niger to provide a more 
detailed account of the cause of death of children in each 
study group. In this study, we report the causes of child 
deaths in Niger, as assessed from this full questionnaire. 
No changes were made to the study design or sample size 
after the trial commenced.
The unit of randomisation in Niger was the grappe: a 
government-defined demo graphic unit analogous to a 
village. Communities located in the Boboye or Loga 
departments with a population of 200–2000 citizens, 
according to the most recent (2012) government census, 
were eligible for enrolment. A study census was done 
in each community approximately every 6 months 
commencing from Nov 23, 2014, up to July 31, 2017. 
Children aged 1–59 months identified in the census were 
eligible for treatment with azithromycin or placebo, and 
their vital status was updated at the following census. 
Children weighing less than 3800 g were excluded from 
treatment, but not from the census. If an eligible child 
was reported as having died, a verbal autopsy was 
attempted. Verbal autopsies were done between May 26, 
2015, and May 17, 2018. It should be noted that, although 
this study activity was termed a census because of the 
door-to-door nature of data collection, this activity was 
analogous to a cohort with open enrolment and repeated 
follow-up visits. Ethical approval was obtained from the 
Committee on Human Research at the University of 
California, San Francisco, and the Institutional Review 
Board of the Nigerien Ministry of Health. Caregivers of 
children provided oral informed consent for treatments 
and verbal autopsies.
Randomisation and masking
Community clusters in Niger were randomly assigned 
(1:1) to either the azithromycin group or the placebo 
group. The trial biostatistician generated the random 
allocation sequence without restriction using the 
R statistical package (version 3). The Nigerien study 
Research in context
Evidence before this study
The Macrolides Oraux pour Réduire les Décès avec un Oeil sur la 
Résistance (MORDOR) trial was a cluster-randomised trial of 
mass biannual azithromycin administration in three countries 
in sub-Saharan Africa. The results showed a 13·5% overall 
reduction in mortality in children aged 1–59 months in 
communities that received azithromycin twice yearly.
Added value of this study
We report verbal autopsy results for childhood deaths that 
occurred in communities located at the Niger site of the 
MORDOR trial. Fewer childhood deaths due to malaria, 
dysentery, meningitis, and pneumonia were reported in 
communities that received azithromycin than in communities 
that received placebo; however, no difference in the overall 
distribution of causes of death was found between the 
two study groups.
Implications of all the available evidence
Community-wide biannual azithromycin distribution reduced the 
number of childhood deaths attributable to infectious diseases in 
Niger. The lack of difference in the distribution of causes of death 
between communities that received azithromycin and those that 
received placebo could be attributable to the broad spectrum of 
azithromycin activity.
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coordinator enrolled communities and assigned them to 
receive the allocated intervention, and also coordinated all 
aspects of the trial before and after randomisation.The 
trial biostatistician analysed the results of the trial. 
Allocation concealment (ie, preventing study investigators 
responsible for enrolling participants from knowing 
which participant would receive which treatment) was 
done at the cluster level by enrolling all communities 
before randomisation, and concealment was done at the 
individual level by administering the treatment to all 
eligible children. Bottles were labelled with one of ten 
treatment letters, with five letters corresponding to 
azithromycin and five letters corresponding to placebo. 
Study bottles, packaging, and the appearance of the drug 
were identical between the two treatment groups. Apart 
from the trial biostatistician, all study participants, field 
personnel, and investigators were masked to treatment 
allocation.
Procedures
Study drugs consisted of either azithromycin powder for 
suspension (200 mg/5 mL) or an identically packaged 
placebo powder (both provided by Pfizer). Children 
aged 1–59 months were given a volume of suspension 
corresponding to at least 20 mg/kg azithromycin or the 
analogous volume of placebo. Suspension volumes 
were estimated by use of a height stick for children 
who could stand and were estimated by weight with a 
digital hanging scale (American Weigh Scales, Cumming, 
GA, USA) for children who could not stand.7 Drug 
administration was directly observed by study personnel. 
Caregivers (ie, the adult responsible for the child, usually 
a parent) were told to contact a community representative 
if adverse events occurred within 7 days of the child 
receiving the drug. A formal adverse events survey was 
done for study participants aged 1–5 months.8
The 2007 WHO questionnaire for children aged from 
4 weeks to 14 years was used for the verbal autopsy. This 
instrument was chosen because it was the most widely 
used survey at the time the study was started (2014).9 The 
primary caregiver was interviewed at their household 
by medical officers masked to the treatment groups. 
All interviewers received biannual training. Seasonal 
migration is common in the study area of Niger (Loga 
and Boboye); therefore locating the households of 
deceased children was sometimes difficult. Before a child 
was considered absent or missing, at least three separate 
visits had to be made to their household. The date of 
death was ascertained independently from both the 
verbal autopsy and the census (with an intraclass 
correlation coefficient of 0·88 [95% CI 0·87–0·89] 
comparing date estimates from the two collection 
methods).
Cause of death was ascertained from the verbal autopsy 
interviews in three ways. First, a single cause of 
death was assigned to each child by use of an adapted 
version of a pre-defined algorithm described previously 
(appendix pp 3–5).10,11 The algorithm had been tested in a 
separate study10 in Niger and was found to provide a 
distribution of cause of death similar to that of physician 
coding. This algorithm first classified the presence or 
absence of one of 17 potential causes of death, and then it 
assigned the primary cause of death on the basis of a 
hierarchy. Four causes of death (diarrhoea, dysentery, 
malaria, and pneumonia) were subclassified as possible 
or probable by the algorithm. Possible and probable 
deaths were ultimately combined when classifying the 
final cause of death for statistical analyses. Similarly, 
malnutrition was subclassified into two types: underlying 
malnutrition, whereby the clinical signs occurred as the 
first element of the illness, and non-underlying, whereby 
the clinical signs occurred later. These subclassifications 
of malnutrition were ultimately combined when 
classifying the final cause of death. Second, the algorithm 
was implemented without the hierarchy, allowing 
multiple causes of death to be assigned to a child. Finally, 
the raw verbal autopsy interview responses were treated 
as a multivariate outcome using the answers to all 
dichotomous questions that were required from all 
respondents (appendix p 6).
Outcomes
The primary outcome of the MORDOR trial was all-cause 
mortality among children aged 1–59 months, as assessed 
biannually by use of a door-to-door census. The results of 
the primary outcome have been published previously.6 A 
prespecified secondary outcome was cause of death as 
assessed by verbal autopsy for all deaths identified during 
the census. Verbal autopsies also functioned as validation 
of vital status reporting from the census. However, the 
prespecified primary outcome of the trial was based only 
on the information obtained from the census and was 
not updated with any additional information obtained 
from the verbal autopsy.
Statistical analysis
The four intercensal periods of the study, which took 
place from Nov 23, 2014, to July 31, 2017, were analysed 
separately. Deaths were counted only if the child had 
been documented as alive and living in the household 
at the biannual census 6 months previously.6 The 
distribution of causes of death between the two study 
groups were compared by use of a permuted χ² test 
with Monte Carlo resampling (10 000 permutations at 
the community level; prespecified primary analysis). In 
a prespecified secondary multivariate analysis, the 
hierarchy was not applied and each child was instead 
allowed to be assigned multiple causes of death (ie, a 
binary response for each of the 12 individual causes of 
death plus a binary indicator for an unspecified cause), 
with a permutational MANOVA (PERMANOVA) used 
to analyse differences between the two study groups 
(Euclidean distance matrix, 10 000 permutations at the 
community level). We chose to use a PERMANOVA 
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because this statistical technique accommodates multiple 
response variables using a non-parametric permutation 
approach.12 A similar PERMANOVA test was used to 
analyse the raw verbal autopsy responses. In additional 
secondary analyses, the incidence rate ratio (IRR) for 
each cause of death was calculated from a negative 
binomial regression that modelled the number of cause-
specific deaths per community as a function of the 
randomisation group, with total person-time as an offset. 
Negative binomial regression was chosen to model the 
count data because this method contains a parameter to 
adjust for overdispersion (eg, an excessive number of 
zeros).13 R version 3 was used for statistical analyses. 
Sample size calculations for the trial were based on 
the primary all-cause mortality outcome.6 Inclusion of 
290 communities in each study group would provide 
80% power to detect a 30% relative difference in any 
specific cause of death between the two study groups, 
assuming a mortality rate of 0·5% per year (ie, five deaths 
per 1000 person-years) in the placebo group, a coefficient 
of variation of 0·51, a population of 111 children per 
community, 10% loss to follow up, and an α level of 0·05. 
A data safety and monitoring committee oversaw the 
study (appendix p 2). This study is registered with 
ClinicalTrials.gov, NCT02047981.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Results
Between Nov 23, 2014, and July 31, 2017, 303 communities 
in the Niger site of the MORDOR trial received biannual 
mass azithromycin distributions and 291 communities 
received biannual mass placebo distributions targeted to 
children aged 1–59 months (figure 1). At baseline, 
40 345 children were enrolled in the azithromycin group 
and 35 747 children in the placebo group (table 1). 
Treatment coverage was high in both groups, with a 
mean coverage of 90·3% (SD 10·6) in communities 
assigned to the azithromycin group and 90·4% (10·1) in 
communities assigned to the placebo group across 
the four mass drug distribution periods (appendix p 7). 
No hospitalisations or life-threatening illnesses were 
reported as a result of study medication in either group 
over the duration of the study, although most children 
had no access to a hospital.
Over 2 years of biannual censuses, 1727 child deaths 
were documented in the azithromycin group, and 
1888 child deaths were documented in the placebo 
group. Verbal autopsy interviews were completed for 
1590 (92·1%) child deaths in the azithromycin group and 
1749 (92·6%) child deaths in the placebo group. The 
median time from the reported date of death until 
completion of the verbal autopsy was 6 months (IQR 2–13) 
in the azithromycin group and 7 months (3–14) in the 
placebo group. The verbal autopsy confirmed the census 
death outcome (ie, a child reported as alive at an initial 
census and then deceased at the subsequent census) for 
3301 (98·9%) of 3339 cases, with the remainder of verbal 
autopsies reporting a stillbirth or miscarriage (n=5 
[0·1%]), or a child who had not died (n=33 [1·0%]; table 2). 
Figure 1: Trial profile
The average number of children per cluster who received azithromycin or placebo and the average number of 
children per cluster who did not receive either treatment despite being randomised to that arm are provided in the 
appendix (p 7). *Ineligible clusters were those that had a population of fewer than 200 persons or more than 
2000 persons on the most recent census, or communities present on the most recent government census but not 
required for the target sample size of the study. †Refers to communities on the government census that no longer 
existed by the time the study census was done. ‡False-positive deaths included children who were recorded as 
deceased on the census but were recorded as alive on the verbal autopsy.
732 community clusters assessed for 
eligibility from most recent census 
646 community clusters assessed for 
eligibility from most recent census 
86 ineligible clusters excluded* 
31 clusters randomised to other studies
308 clusters randomised to biannual 
azithromycin group
303 clusters (40 345 children at 
baseline) allocated to receive 
azithromycin
1727 child deaths recorded on census
1590 verbal autopsies completed for 
children
1566 verbal autopsies for children 
(303 clusters) analysed
5 non-existent clusters excluded† 
137 children lost to follow-up
136 households not located
1 caregiver refused to 
provide verbal autopsy
24 verbal autopsies excluded
22 false-positive deaths‡
2 children were stillborn on 
autopsy
307 clusters randomised to biannual 
placebo group
291 clusters (35 747 children at 
baseline) allocated to receive
placebo
1888 child deaths recorded on census
1749 verbal autopsies completed for 
children
1735 verbal autopsies for children 
(291 clusters) analysed
16 clusters excluded
15 non-existent clusters†
1 refused to participate
139 children lost to follow-up 
because households were not 
located
14 verbal autopsies excluded
11 false-positive deaths‡
3  children were stillborn on 
autopsy
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Discrepancies between the census and verbal autopsy for 
the reported vital status of children were slightly more 
common in the azithromycin group (22 [1·3%] of 
1727 children identified as having died in the census were 
found to be alive during the verbal autopsy) than the 
placebo group (11 [0·6%] of 1888 children identified as 
having died in the census were found to be alive during 
the verbal autopsy).
Table 3 shows the primary cause of death in children 
(as identified by the pre-defined algorithm) and the 
incidence estimates for each cause of death. Figure 2 
shows the effect of azithromycin treatment on cause-
specific mortality in children relative to placebo, with 
causes of death listed in descending order of strength 
of association. Relative to mass placebo distribution, 
mass azithromycin distribution was most significantly 
associated with a reduction in the number of child 
deaths due to malaria (IRR 0·78, 95% CI 0·66–0·92; 
p=0·0029), followed by dysentery (0·65, 0·44–0·94; 
p=0·025), meningitis (0·67, 0·46–0·97; p=0·036), and 
pneumonia (0·83, 0·68–1·00; p=0·051). Mass 
azithromycin distribution had no significant effect on 
the number of child deaths due to viruses (ie, AIDS, 
haemorrhagic fever, and measles) or non-infectious 
causes (ie, injury and malnutrition; figure 2), and when 
these five causes were pooled together, cause-specific 
mortality was similar between the two treatment groups 
(1·00, 0·72–1·40; p=0·981).
The distribution of child deaths did not differ between 
the two groups (p=0·980). This result remained not 
significant when child deaths attributable to probable or 
possible malnutrition were analysed separately 
(p=0·962), when infectious causes of death were 
compared with non-infectious causes (p=0·766), when 
multiple causes of death were allowed for each child 
(p=0·733), and when raw verbal autopsy responses were 
used (p=0·058).
Discussion
The MORDOR trial was a placebo-controlled, community-
randomised trial that found an 18% reduction in all-cause 
mortality among children aged 1–59 months in Nigerien 
communities that received biannual mass azithromycin 
treatment. The causes of death of children in this trial 
have been reported previously,6 but cause of death was 
ascertained in that report by use of a shortened verbal 
autopsy instrument. In this present study, we report the 
results from interviews done using the full 2007 WHO 
verbal autopsy instrument. The distribution of child 
deaths in the azithromycin and placebo groups in the 
present study was largely similar to the distribution of 
child deaths observed when the abbreviated verbal 
autopsy was used. However, the full verbal autopsy 
instrument detected fewer cases of malaria and more 
cases of respiratory infection than did the shortened 
instrument. Cause-specific mortality among children 
aged 1–59 months was significantly lower in the 
azithromycin group than the placebo group for several 
causes of death due to infectious diseases. However, the 
distribution of causes of death was not significantly 
different between the azithromycin and placebo group.
One reason verbal autopsies were conducted in the 
MORDOR trial was to validate child deaths reported in 
the censuses. An independent team of field personnel 
conducted the verbal autopsies, which were attempted 
for all deaths identified during the census. We found that 
a death identified during the census in Niger had a 
98·8% positive predictive value based on the verbal 
autopsy results. False-positive deaths (ie, children who 
were reported as deceased on the census but were 
reported as alive on the verbal autopsy) were slightly 
more common in the azithromycin group, suggesting 
that biased ascertainment of child deaths during the 
census did not account for the observed reduction in 
child mortality in the azithromycin group versus the 
placebo group in the MORDOR trial.
We used the 2007 WHO verbal autopsy questionnaire 
combined with an expert hierarchical algorithm used in 
previous studies in Niger9–11 to assign a single cause of 
death to each child. Other instruments with a slightly 
different set of questions are available (eg, instruments 
from WHO, the Population Health Metrics Research 
Consortium, and the INDEPTH network, among others), 
Azithromycin group 
(303 communities) 
Placebo group 
(291 communities)
Mean number of children 
per community
133 (93) 123 (88)
Percentage of children by age group
1–11 months 20·2% (6·1) 20·5% (6·1)
12–23 months 17·0% (5·1) 16·8% (5·3)
24–35 months 21·2% (4·9) 21·0% (5·2)
36–47 months 21·7% (5·6) 21·1% (4·8)
48–59 months 19·9% (10·5) 20·6% (10·2)
Percentage of male 
children
51·2% (6·2) 51·4% (6·4)
Data are mean (SD).
Table 1: Baseline characteristics of communities from the initial census
Azithromycin group 
(n=1727)
Placebo group 
(n=1888)
Verbal autopsy not performed
Household not located 136 (7·9%) 139 (7·4%)
Caregiver refused 1 (0·1%) 0 (0%)
Verbal autopsy performed
Child reported as alive 22 (1·3%) 11 (0·6%)
Child reported as stillborn or 
miscarriage
2 (0·1%) 3 (0·2%)
Cause of death ascertained 1566 (90·7%) 1735 (91·9%)
Data are n (%).
Table 2: Outcomes of the verbal autopsy interview
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as are alternate analysis methods, such as a physician 
review, different algorithms, and Bayesian methods.14–17 
None of the instruments or analysis techniques have 
perfect diagnostic accuracies, and each method is likely to 
misclassify a proportion of deaths, particularly those 
associated with vague or non-specific symptoms, such as 
malaria.11,18,19 Although it is possible that the use of a 
different questionnaire or analysis method would have 
resulted in slightly different estimates, the overall 
conclusions of our analysis are likely to be robust given 
the randomisation and masking methods used in the trial.
The distribution of the causes of death among children 
observed in the present study is consistent with other 
studies from Niger that have used verbal autopsy 
questionnaires. For example, Kalter and colleagues10 
used a similar algorithmic approach to analyse 620 child 
deaths in Niger from 2007 to 2010 and found that the 
predominant causes of death among children aged 
1–59 months were malaria (29%), diarrhoea (20%), 
meningitis (18%), and pneumonia (12%). By comparison, 
the predominant causes of death found in the present 
study were malaria (28%), diarrhoea (15%), pneu-
monia (16%), and meningitis (4%). Other studies2,20 have 
reported similar estimates of the distribution of causes 
of childhood mortality in Niger, with mortality estimates 
for meningitis more consistent with those reported in 
our study than those from the study by Kalter and 
colleagues.10 
We found that mass azithromycin distribution did not 
significantly alter the distribution of the causes of child 
deaths in Niger compared with mass distribution of 
placebo. One possible explanation for this result could be 
that most child deaths after the first month of life were 
due to infections, and the broad spectrum of activity of 
azithromycin acted against a range of bacterial and 
parasitic microorganisms responsible for these deaths, 
as suggested by our analysis. Thus, mass azithromycin 
distribution could have resulted in a small reduction in 
many causes of death due to infectious diseases, leading 
to a substantial reduction in the overall mortality of 
children, but only small changes in the proportion of 
deaths due to any specific cause.
Azithromycin group Placebo group Incidence rate ratio (95% CI) p value
Number of children (%) Incidence (95% CI) Number of children (%) Incidence (95% CI)
Non-infectious cause
Injury 17 (1·1%) 0·22 (0·14–0·36) 16 (0·9%) 0·23 (0·14–0·38) 0·95 (0·48–1·90) 0·883
Malnutrition* 31 (2·0%) 0·39 (0·26–0·59) 29 (1·7%) 0·42 (0·28–0·63) 0·93 (0·53–1·66) 0·816
Underlying 4 (0·3%) 0·05 (0·02–0·14) 6 (0·3%) 0·09 (0·04–0·19) 0·60 (0·15–2·09) 0·423
Non-underlying 27 (1·7%) 0·35 (0·23–0·53) 23 (1·3%) 0·33 (0·21–0·52) 1·05 (0·57–1·95) 0·881
Infectious cause
AIDS 9 (0·6%) 0·12 (0·06–0·23) 8 (0·5%) 0·12 (0·06–0·24) 0·99 (0·37–2·71) 0·990
Measles 23 (1·5%) 0·30 (0·19–0·46) 19 (1·1%) 0·28 (0·17–0·45) 1·08 (0·56–2·08) 0·823
Meningitis 63 (4·0%) 0·82 (0·63–1·09) 83 (4·8%) 1·22 (0·96–1·57) 0·67 (0·46–0·97) 0·036
Dysentery 57 (3·6%) 0·74 (0·55–0·98) 77 (4·4%) 1·14 (0·88–1·47) 0·65 (0·44–0·94) 0·025
Probable 21 (1·3%) 0·28 (0·18–0·43) 38 (2·2%) 0·56 (0·40–0·79) 0·49 (0·27–0·86) 0·014
Possible 36 (2·3%) 0·47 (0·33–0·65) 39 (2·2%) 0·57 (0·41–0·78) 0·82 (0·51–1·30) 0·399
Diarrhoea 234 (14·9%) 3·01 (2·59–3·49) 251 (14·5%) 3·60 (3·11–4·17) 0·83 (0·68–1·03) 0·088
Probable 104 (6·6%) 1·37 (1·10–1·70) 114 (6·6%) 1·66 (1·34–2·05) 0·82 (0·61–1·12) 0·214
Possible 130 (8·3%) 1·65 (1·36–2·01) 137 (7·9%) 1·96 (1·61–2·36) 0·84 (0·65–1·11) 0·223
Pertussis 3 (0·2%) 0·04 (0·01–0·12) 3 (0·2%) 0·04 (0·01–0·14) 0·89 (0·17–4·83) 0·891
Pneumonia 252 (16·1%) 3·27 (2·85–3·75) 275 (15·9%) 3·96 (3·46–4·53) 0·83 (0·68–1·00) 0·051
Probable 81 (5·2%) 1·06 (0·83–1·36) 97 (5·6%) 1·40 (1·11–1·77) 0·76 (0·54–1·06) 0·107
Possible 171 (10·9%) 2·22 (1·89–2·59) 178 (10·3%) 2·57 (2·20–3·01) 0·86 (0·69–1·07) 0·186
Malaria 437 (27·9%) 5·60 (4·97–6·32) 493 (28·4%) 7·22 (6·43–8·11) 0·78 (0·66–0·92) 0·003
Probable 57 (3·6%) 0·74 (0·57–0·96) 53 (3·1%) 0·77 (0·59–1·01) 0·96 (0·66–1·40) 0·837
Possible 380 (24·3%) 4·89 (4·29–5·57) 440 (25·4%) 6·45 (5·69–7·31) 0·76 (0·63–0·91) 0·003
Haemorrhagic fever 6 (0·4%) 0·08 (0·03–0·17) 4 (0·2%) 0·06 (0·02–0·16) 1·34 (0·38–5·25) 0·650
Other infection 325 (20·8%) 4·24 (3·70–4·85) 354 (20·4%) 5·06 (4·44–5·78) 0·84 (0·69–1·01) 0·063
Unspecified 109 (7·0%) 1·43 (1·17–1·75) 123 (7·1%) 1·81 (1·49–2·19) 0·79 (0·60–1·05) 0·104
Total 1566 (100·0%) 22·32 (20·86–23·87) 1735 (100%) 27·26 (25·50–29·13) 0·82 (0·75–0·90) <0·001
Primary cause of death was assessed by use of a hierarchical algorithm. Incidence is reported as deaths per 1000 person-years, estimated from a negative binomial regression of community-level death counts, 
with total community person-time determined from the census used as the offset. *Underlying malnutrition is defined by the occurrence of clinical signs of malnutrition as the first element of the illness, whereas 
clinical signs of malnutrition occur later in non-underlying malnutrition.
Table 3: Primary cause of death ascertained from verbal autopsy
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The benefit of azithromycin was most pronounced 
for deaths due to malaria, meningitis, dysentery, and 
pneumonia. Although this finding could be explained, 
in part, because these diseases were the most common 
causes of death in children and therefore provided the 
most statistical power to detect a difference in treatment 
effect, azithromycin has a plausible treatment effect for 
each of these causes of death. Azithromycin has 
moderate anti-malarial activity because of its effects on 
the plasmodial apicoplast.21 Indeed, a sister trial done 
alongside the MORDOR trial found a reduction in the 
prevalence of malaria parasitaemia in communities 
that received azithromycin.22 The main causes of 
bacterial meningitis in Niger are Neisseria meningitidis, 
Streptococcus pneumoniae, and Haemophilus influenzae; 
S pneumoniae and H influenzae are also the major 
microorganisms that cause pneumonia.23,24 The primary 
cause of bacillary dysentery is shigella, Escherichia coli, 
and Campylobacter spp.25 All of these bacteria are 
susceptible to azithromycin.
The mechanism of action by which mass azithromycin 
distribution reduces childhood mortality is unclear. 
Mass therapy with azithromycin has been speculated to 
clear established infections early in the disease course, 
thereby preventing mortality. Alternatively, azithromycin 
might clear commensal organisms (eg, nasopharyngeal 
pneumococcus), thus preventing the carriage of such 
organisms and the development of invasive infections. 
Azithromycin might also act as a prophylactic therapy 
that prevents children from acquiring an infection in the 
first instance. Besides these potential activities against 
specific pathogenic organisms, it is also possible that 
azithromycin serves a role as a modulator of the 
microbiota or of inflammatory mediators, which could, 
in turn, be protective against mortality. Alternatively, 
azithromycin could promote the growth of children by 
indirectly improving the health of their immune 
systems, leading to less severe infections. Ultimately, the 
mechanisms by which mass azithromycin distribution 
reduces mortality in children remains a matter of 
speculation, and further research is needed to identify 
the exact mechanisms.
Antibiotic resistance could theoretically reduce the 
activity of azithromycin for some bacterial pathogens, 
although macrolide antibiotics are not widely prescribed 
in Niger. Mass azithromycin distributions could select 
for resistant bacteria, although limiting the distribution 
of antibiotic treatments to children aged 1–59 months 
rather than to individuals of all ages (as is done in 
trachoma programmes) could reduce the antibiotic 
selection pressure.
Attributing a cause of death outside of the health-care 
system is difficult, especially in resource-limited 
settings.26 The most common technique currently used 
to address this problem is the verbal autopsy, whereby 
the caregivers of a deceased child are asked a series of 
questions designed to identify the signs of the final 
illness. However, this method of data collection has 
some shortcomings. Caregivers might not understand 
the terminology used in the verbal autopsy questionnaire, 
which could lead to incorrect reporting of the cause of 
death. For example, a previous study27 found that a fifth 
of neonatal deaths were misclassified as stillbirths—an 
error that also occurred in a few cases in the present 
study. In addition, caregivers might forget key details of 
the child’s symptoms between the time of death and the 
interview. Furthermore, not all parents can be located 
after a child death is reported, which leads to incomplete 
information. Cause of death is established by the 
caregiver report, without any added information about 
vital signs or a physical examination by a health-care 
professional (eg, a medical doctor, medical officer, or a 
nurse). Many children will exhibit signs and symptoms 
of several different diseases; therefore, attributing a 
single cause of death can be difficult. Despite the 
limitations of the verbal autopsy, it is the most realistic 
option in resource-limited settings. Having cause of 
death determined by a health-care provider would be 
ideal, but was not feasible in the Niger study site, where 
few children are seen by a health-care provider during 
the final illness. Other methods, such as minimally 
invasive tissue sampling, could have provided more 
robust information; however, these tests were not 
included in the MORDOR trial, which was specifically 
designed to collect data on a small number of straight-
forward outcome measures from a large sample 
population.28,29
Aside from the challenges of the verbal autopsy 
method, our study has several other limitations. 
As described above, the verbal autopsy method is subject 
to data misclassification during data collection and 
Figure 2: Forest plot showing the effect of mass azithromycin distribution 
on cause-specific mortality in children younger than 5 years in Niger
The incidence rate ratio estimates and 95% CIs are shown for each cause of death, 
as determined from the verbal autopsy. The estimates are ordered by degree of 
statistical significance (from strongest association to weakest association).
AIDS
Pertussis
Injury
Measles
Malnutrition
Haemorrhagic fever
Ca
us
e o
f d
ea
th
Unspecified
Diarrhoea
Other infection
Pneumonia
Meningitis
Dysentery
Malaria
0 0·25 0·50 1·00 2·00 4·00
Incidence rate ratio
Higher in 
placebo group
Higher in 
azithromicin group
Articles
e295 www.thelancet.com/lancetgh   Vol 8   February 2020
analysis. Although this error would limit statistical 
power, differential misclassification between treatment 
groups would not be expected because of the randomised 
nature of the study. A verbal autopsy interview was not 
completed for all child deaths, and it is possible that 
deaths lost to follow-up might have been systematically 
different from deaths for which a verbal autopsy 
was completed. However, the proportion of child deaths 
for which verbal autopsies were completed was 
approximately 90% in both groups, making differential 
loss to follow-up unlikely. The generalisability of the 
findings outside, and even within, Niger is unclear, 
especially for those infectious diseases with marked 
geospatial patterns, such as meningitis and malaria.
In summary, verbal autopsy results from the Niger site 
of the MORDOR trial revealed that mass azithromycin 
distribution to children aged 1–59 months had the most 
significant effect for deaths due to malaria, meningitis, 
dysentery, and pneumonia. Azithromycin has a plausible 
mechanism of action against the pathogenic causes of 
each of these conditions. Mass azithromycin treatments 
did not change the distribution of causes of death among 
deceased children, perhaps because most deaths were 
due to infectious causes and were therefore potentially 
susceptible to the broad-spectrum activity of azithromycin. 
If mass azithromycin distribution results in a general 
reduction in child deaths due to infectious causes, then 
this antibiotic would be expected to be most effective in 
settings with a high burden of mortality due to infectious 
diseases, such as in Niger.
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